title: [Prognostic factors of stage IB and IIA carcinoma of the cervix treated by surgery].
abstract: OBJECTIVE
  To evaluate prognostic factors in patients with stage IB-IIA of cervical carcinoma treated by surgery.
  
  
  METHODS
  Between December 1992 and December 2001, 111 patients with stage IB-IIA cervical cancer surgically treated were analyzed. Median age 40 years. According to 1994 FIGO Staging System: IB 80 (IB1 40, IB2 40) and IIA 31. There were 93 cases of squamous cell carcinoma (83.5%), 17 cases of adenocarcinoma (15.3%) and one case of small cell carcinoma. All patients were treated by radical hysterectomy and pelvic lymphadenectomy, 74 patients had preoperative adjuvant radiotherapy, 24 patients had postoperative adjuvant treatment. Kaplan-Meier method was used to evaluate the survival, the related prognostic factors were assessed by Cox regression and chi(2) test.
  
  
  RESULTS
  The overall 5-year survival rate was 85.9%, being 89.1%, 90.7% and 78.4% for stage IB1, IB2 and IIA, respectively. Univariate analysis showed that tumor size (hazards ratio [HR] = 1.479, P = 0.152), tumor type (HR = 1.440, P = 0.264), clinical stage (HR = 1.380, P = 0.354), adjuvant treatment (HR = 1.210, P = 0.450), lymph node metastasis (HR = 1.432, P = 0.540), endocervical involvement (HR = 2.244, P = 0.036), depth of myometrial invasion (HR = 3.295, P = 0.06) and multiple sexual partners during pregnancy (HR = 10.172, P = 0.000) were of prognostic significance. The latter two were the most important factors indicative of poor prognosis.
  
  
  CONCLUSIONS
  The depth of myometrial invasion and multi-partners combined with pregnancy are closely related to the prognosis while the pre- and/or postoperative adjuvant therapy should be considered for stage IB-IIA cervical cancer with deep myometrial invasion and in pregnant patients with multiple sexual partners.
authors.affiliation: Department of Gynecologic Oncology, Cancer Institute (Hospital), Chinese Academy Of Medical Sciences, Peking Union Medical College, Beijing 100021, China.
authors.forename: Wen-Hua
authors.initials: WH
authors.lastname: Zhang
authors.forename: Ling-Ying
authors.initials: LY
authors.lastname: Wu
authors.forename: Ping
authors.initials: P
authors.lastname: Bai
authors.forename: Shu-Min
authors.initials: SM
authors.lastname: Li
authors.forename: Rong
authors.initials: R
authors.lastname: Zhang
authors.forename: Bin
authors.initials: B
authors.lastname: Li
authors.forename: Jian-Heng
authors.initials: JH
authors.lastname: Sun
authors.forename: Ai-Ru
authors.initials: AR
authors.lastname: Wu
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000601:surgery*; D000293:Adolescent; D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000473:pathology / Q000601:surgery; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D015996:Survival Rate; D047368:Tumor Burden; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000601:surgery*